MCP
BCLI

Mirador Capital Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Mirador Capital Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,768
Closed -$5.31K – 185
2023
Q3 		$5.31K Buy
1,768
+96
+6% +$2.18K ﹤0.01% 184
2023
Q2 		$51.7K Buy
+1,672
New +$69.3K 0.01% 186

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Mirador Capital Partners's BCLI Position: Q4 2023 in Review

Mirador Capital Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 1,768 shares — an estimated $5.31K sold.

Mirador Capital Partners first reported a position in BCLI in Q2 2023 and held it in 2 quarters. The position peaked at $51.7K in Q2 2023. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • Mirador Capital Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • Mirador Capital Partners sold 1,768 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $5.31K.
  • Mirador Capital Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2023 and held it in 2 quarters.
  • Mirador Capital Partners's BRAINSTORM CELL THERAPUTC position peaked at $51.7K in Q2 2023.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Mirador Capital Partners's 13F filing for Q4 2023, filed 19 Jan 2024.